Literature DB >> 23907933

Injectable tissue-engineered cartilage using commercially available fibrin glue.

Ozcan Cakmak1, Seda T Babakurban, Hatice G Akkuzu, Selcuk Bilgi, Ercüment Ovalı, Merve Kongur, Hande Altintas, Bayram Yilmaz, Banu Bilezikçi, Zerrin Y Celik, Mustafa C Yakicier, Feride I Sahin.   

Abstract

OBJECTIVES/HYPOTHESIS: To achieve injectable tissue-engineered cartilage using a commercially available fibrin sealant, and to determine the most suitable fibrin glue concentration, cartilage source, and cultured chondrocyte concentration. STUDY
DESIGN: Animal research.
METHODS: A total of 28 immunocompetent New Zealand white rabbits were divided into four groups. The cultured chondrocytes from different anatomical sources carried in fibrin glue with and without aprotinin in different concentrations of fibrinogen and thrombin (Tisseell), were injected into forehead and interocular regions of the rabbits. The new tissue formation was harvested at 8 weeks and analyzed through gross and histological analysis.
RESULTS: The new tissue formations were found in round, elliptical, and flat forms. The mean value of Tisseell and cell suspension was 0.8 cc in all of the rabbits' injection regions, but the mean volume of the samples in which immature cartilage matrix and mature cartilage was 0.1 cc. In the 20 of the 55 injection regions of rabbits (36, 36%), mature and/or immature cartilage formation were observed. We observed inflammatory reactions, abscess formation, and foreign body reactions around the new cartilage tissue of tissue-engineered cartilage. The comparison of results using different cartilage sources, chondrocyte concentrations, or different fibrin glue concentrations did not show any significant difference.
CONCLUSIONS: We observed that changing the concentrations of ingredients of commercially available fibrin glue, the source of the cartilage, or the cultured chondrocyte concentration did not have significant effect on neocartilage formation.
Copyright © 2013 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Issue engineering; cartilage; fibrin glue; immunocompromised

Mesh:

Substances:

Year:  2013        PMID: 23907933     DOI: 10.1002/lary.24156

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Bio-engineering of fetal cartilage for in utero spina bifida repair.

Authors:  Athanasia Dasargyri; Ernst Reichmann; Ueli Moehrlen
Journal:  Pediatr Surg Int       Date:  2019-10-01       Impact factor: 1.827

Review 2.  Fibrin gel as an injectable biodegradable scaffold and cell carrier for tissue engineering.

Authors:  Yuting Li; Hao Meng; Yuan Liu; Bruce P Lee
Journal:  ScientificWorldJournal       Date:  2015-03-17

3.  Repair of full-thickness articular cartilage defects using IEIK13 self-assembling peptide hydrogel in a non-human primate model.

Authors:  Emeline Perrier-Groult; Frédéric Mallein-Gerin; Alexandre Dufour; Jérôme E Lafont; Marie Buffier; Michaël Verset; Angéline Cohendet; Hugues Contamin; Joachim Confais; Sharanya Sankar; Marika Rioult
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

4.  An Injectable Platform of Engineered Cartilage Gel and Gelatin Methacrylate to Promote Cartilage Regeneration.

Authors:  Wei Xu; Tao Wang; Yahui Wang; Xiaodi Wu; Yujie Chen; Daiying Song; Zheng Ci; Yilin Cao; Yujie Hua; Guangdong Zhou; Yu Liu
Journal:  Front Bioeng Biotechnol       Date:  2022-04-14

Review 5.  Reconstruction of Craniomaxillofacial Bone Defects Using Tissue-Engineering Strategies with Injectable and Non-Injectable Scaffolds.

Authors:  Bipin Gaihre; Suren Uswatta; Ambalangodage C Jayasuriya
Journal:  J Funct Biomater       Date:  2017-11-20

6.  Porcine fibrin sealant combined with autologous chondrocytes successfully promotes full-thickness cartilage regeneration in a rabbit model.

Authors:  Yu Yang; Xin Wang; Kangkang Zha; Zhuang Tian; Shuyun Liu; Xiang Sui; Zhigang Wang; Jilian Zheng; Jun Wang; Xiaobin Tian; Quanyi Guo; Jinmin Zhao
Journal:  J Tissue Eng Regen Med       Date:  2021-06-04       Impact factor: 3.963

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.